TVRD — Tvardi Therapeutics Share News
0.000.00%
Last trade - 00:00Cara Therapeutics down on lower-than-expected Q4 sales
Cara Therapeutics down on lower-than-expected Q4 sales
U.S. RESEARCH ROUNDUP-Esperion Therapeutics, Office Properties Income Trust, Radius Global Infrastructure
Brief: Cara Therapeutics Announces Q4 And Full Year 2022 Financial Results
Cara Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Cara Therapeutics Q4 revenue USD 3.261 million
Cara Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Linkbancorp, Oyster Point Pharma, Viatris
Brief: Cara Therapeutics Reports Third Quarter 2022 Financial Results
Cara Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Cara Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Cara Therapeutics Announces Appointment Of Lisa Von Moltke To Its Board Of Directors
Brief: SWK Holdings Says Unit Receives $5 Mln Milestone Payment From Cara Therapeutics
U.S. STOCKS ON THE MOVE-Heartbeam, Aura Biosciences, U.S. banks
Cara Therapeutics submits marketing application in Japan for pruritus drug
Brief: Cara Therapeutics Announces Difelikefalin Injection New Drug Application Has Been Submitted In Japan
Brief: Cara Therapeutics - Announced Appointment Of Ryan Maynard As CFO
Brief: Cara Therapeutics - Announced Appointment Of Ryan Maynard As Chief Financial Officer
Brief: Cara Therapeutics Presents Late-Breaking Results Of The Komfort Phase 2 Trial Of Oral Difelikefalin For Pruritus In Notalgia Paresthetica At 31St EADV Congress